{{overview_title}}
{{overview_content}}
{{mechanism_title}}
{{mechanism_content}}
{{benefits_title}}
{{research_title}}
{{research_content}}
{{safety_title}}
{{safety_content}}
Recommended products
Research peptides selected for quality and purity:
Top Pick
GHK-Cu
Anti-Aging Compound
Test your knowledge
Quick quiz · 6 questions
Frequently Asked Questions
What does DSIP stand for?
DSIP stands for delta sleep-inducing peptide. The name comes from its 1977 discovery, when researchers isolated it from the blood of rabbits experiencing delta-wave (deep) sleep and observed that infusing it appeared to promote this sleep stage. The name describes how it was discovered rather than a confirmed, reliable effect in humans.
Is DSIP proven to cure insomnia?
No. DSIP is not a proven or approved treatment for insomnia. Some small, mostly decades-old human studies reported modest sleep improvements, but results have been inconsistent and no large, modern randomized controlled trials support its use. Evidence-based options such as CBT-I and good sleep hygiene are far better supported. Consult a healthcare professional for persistent sleep problems.
Is DSIP legal and FDA-approved?
DSIP is not approved by the FDA, EMA, or other major regulators for any medical use. It is sold only as a 'research use only' chemical, which means it is not intended for human consumption. Legal status varies by country, and athletes should note that anti-doping agencies scrutinize unapproved peptides. Verify your local regulations before assuming anything about its legality.
How is DSIP typically administered in research?
In studies and non-clinical use, DSIP has been given by intravenous infusion or subcutaneous injection. Oral administration is considered ineffective because the digestive system breaks the peptide down. DSIP also has a very short half-life of minutes in the bloodstream. Because it is an unregulated research chemical, purity and dosing are not guaranteed, and self-administration carries real risks.
Does DSIP have side effects?
DSIP's safety in humans is poorly characterized. Limited short studies reported it was generally tolerated, but this is not the same as being proven safe. Possible concerns include injection-site reactions, headache, hormonal effects via the hypothalamic-pituitary axis, and unknown long-term effects. The biggest practical risks come from the unregulated supply chain, including contamination and incorrect dosing.
Sources
- Schoenenberger GA, Monnier M. (1977). Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences USA.
- Graf MV, Kastin AJ. (1984). Delta-sleep-inducing peptide (DSIP): a review. Neuroscience & Biobehavioral Reviews.
- Kovalzon VM, Strekalova TV. (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry.
- Schneider-Helmert D, Schoenenberger GA. (1983). Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology.
- Sudakov KV, Umriukhin PE, Rayevsky KS. (2004). Delta-sleep-inducing peptide and neuronal activity after glutamate microiontophoresis: the role of NMDA receptors. Pathophysiology.
- Khvatova EM, Samartzev VN, Zagoskin PP, et al. (2003). Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides.